Pricing for this level typically starts around $429 in-clinic , with mobile delivery increasing the total cost
The combination of structural resistance to DPP-4 and prolonged half-life via HSA fusion allows for once-weekly administration, positioning albiglutide as a viable and efficacious GLP-1 receptor agonist for long-term glycemic control [14]
Employers evaluating GLP-1 strategies must take a holistic view of the forces influencing utilization, cost, and outcomes
There is an annual limit of $1,000 per year (starting in July, ending the following June), but there are no co-pays
The next very important chapter of the story, once we get beyond the weight loss, will be to say, OK, whats the unique character of each one of these partners, and does this bring a unique benefit? Drucker said
This is where you'll see the earliest changes